MedTrace Logo

Prognostic Perspective of Invasive Hyperemic and Non-Hyperemic Physiologic Indices Measured After Percutaneous Coronary Intervention

NCT04265443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 588

Last updated 2022-10-26

No results posted yet for this study

Summary

Coronary physiologic assessments by the pressure-derived fractional flow reserve (FFR) have become standard methods for identifying hemodynamic deprivation in coronary arterial stenosis for evidence-based percutaneous coronary intervention (PCI). Invasive physiologic indices-guidance enables on-site real time assessment for functional significance of epicardial coronary stenosis and the use of those indices has shown to be effective to guide treatment decision. Several studies further support the role of post-PCI FFR measurement as a functional marker of residual disease after PCI and prognostic indicator of patients. Although optimal cut-off values of post-PCI FFR varied across studies, an inverse relationship between post-PCI FFR and the risk of future clinical events have been reported consistently.

Recently, non-hyperemic pressure ratios (NHPRs) have been introduced in clinical practice. Although there are several different NHPRs, previous studies consistently indicated that those NHPRs shares similar diagnostic performance and prognostic implications. Nevertheless, few reports were available for clinical relevance of NHPRs in evaluation of post-PCI status.

In this context, we will evaluate the physiologic characteristics and prognostic implication of post-PCI NHPRs and compare with those of post-PCI FFR in patients who underwent angiographically successful PCI with 2nd generation drug-eluting stent implantation (DES).

Conditions

  • Ischemic Heart Disease

Interventions

DEVICE

Percutaneous coronary intervention

PCI was performed using 2nd generation DES

Sponsors & Collaborators

  • Inje University Ilsan Paik Hospital

    collaborator OTHER

  • Ulsan University Hospital

    collaborator OTHER

  • Sejong General Hospital

    collaborator OTHER

  • Chosun University Hospital

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Joo Myung Lee, MD, MPH, PhD · Samsung Medical Center

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-13
Primary Completion
2022-10-01
Completion
2022-10-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04265443 on ClinicalTrials.gov